Tumour endothelial cell reprogramming orchestrates angiocrine signalling to drive chemoresistance in breast cancer
Angiogenesis · 22.06.2026 · 29 (3)
DOI: 10.1007/s10456-026-10063-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Angiogenesis, online erschienen am 22.06.2026. Verfasst von Jesus Gomez-Escudero und 10 weiteren Autor:innen. Beteiligte Einrichtung: Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London, UK. jesuschgoes@usal.es. Hauptthemen laut MEDLINE: Drug Resistance, Neoplasm, Signal Transduction, Neovascularization, Pathologic, Endothelial Cells. Die Arbeit nennt 93 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CRUK CITY OF LONDON CENTRE AWARD, Worldwide Cancer Research, Medical Research Council.
Abstract (Originalsprache)
Despite its established role in breast cancer treatment, Doxorubicin treatment remains subject to adaptive resistance mechanisms that extend beyond cancer cell intrinsic alterations ultimately reducing therapy efficacy. Our study in a MMTV-PyMT-driven mouse breast cancer model reveals that prolonged Doxorubicin (Dox) exposure triggers significant reprogramming of the tumour vasculature, substantially altering the angiocrine landscape and shaping treatment outcomes. Notably, tumours that initially respond, but later revert, display an endothelial cell subclustering with activation of proliferative and NF-κB-dependent cytokine pathways. We further identify a novel endothelial subpopulation characterised by higher expression of drug clearance and oxidative metabolism markers, suggesting an active role in mitigating Dox efficacy and angiogenesis promotion. These findings substantiate endothelial plasticity as a critical mediator of therapeutic failure. By uncovering these vascular adaptations, our work provides a new perspective on the underlying mechanisms of Dox resistance and the prolonged efficacy of chemotherapy in breast cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London, UK. jesuschgoes@usal.es.
- Biochemistry and Molecular Biology Department, Salamanca University, Salamanca, Spain. jesuschgoes@usal.es.
- Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London, UK.
- UCL Cancer Institute, CRUK City of London Centre Single Cell Genomics Facility, University College London, London, UK.
- Bioinformatics Hub, UCL Cancer Institute, University College London, London, UK.
- Biochemistry and Molecular Biology Department, Salamanca University, Salamanca, Spain.
Förderung
- CRUK CITY OF LONDON CENTRE AWARD
- Worldwide Cancer Research
- Medical Research Council
- Barts Charity
- Cancer Research UK
Zitieren
APA
Gomez-Escudero, J., Maniati, E., Holdsworth, J., Beattie, G., Hijazi, M., Guelbert, M., Elorbany, S., Cutillas, P., Wang, J., Hodivala-Dilke, K., & D'Amico, G. (2026). Tumour endothelial cell reprogramming orchestrates angiocrine signalling to drive chemoresistance in breast cancer. Angiogenesis, 29(3). https://doi.org/10.1007/s10456-026-10063-7
Vancouver
Gomez-Escudero J, Maniati E, Holdsworth J, Beattie G, Hijazi M, Guelbert M, et al. Tumour endothelial cell reprogramming orchestrates angiocrine signalling to drive chemoresistance in breast cancer. Angiogenesis. 2026;29(3). doi:10.1007/s10456-026-10063-7
BibTeX
@article{GomezEscudero2026,
author = {Gomez-Escudero, Jesus and Maniati, Eleni and Holdsworth, Julie and Beattie, Gordon and Hijazi, Maruan and Guelbert, Matt and Elorbany, Samar and Cutillas, Pedro and Wang, Jun and Hodivala-Dilke, Kairbaan and D'Amico, Gabriela},
title = {Tumour endothelial cell reprogramming orchestrates angiocrine signalling to drive chemoresistance in breast cancer},
journal = {Angiogenesis},
year = {2026},
volume = {29},
number = {3},
doi = {10.1007/s10456-026-10063-7}
}
EUVIMED